eight serum samples had neutralizing activity, indicating that the particles produced in W:ADSP-infected cells were immunogenic. Finally, when lysates from W:ADSP-infected cells were compared with standard ADV antigens in counterimmunoelectrophoresis assays, a similar pattern of specific reactivity was observed for sera from normal and infected mink.
Aleutian mink disease parvovirus (ADV) causes a severe disease in mink. The pathogenesis of ADV infections is influenced by the genetic background of the mink, the age at which the animal becomes infected, and the strain of virus (1, 20, 22) . In seronegative neonatal mink, ADV causes a fatal acute pneumonia (1) , whereas ADV infection in adult mink results in a persistent disease characterized by hypergammaglobulinemia, plasmacytosis, arteritis, and fatal immune-complex glomerulonephritis (22, 38, 40, 41) .
Attempts to protect mink from ADV infection by vaccination with either killed or nonpathogenic, cell cultureadapted ADV have proven unsuccessful (10, 39) . In fact, animals receiving such materials have developed more severe forms of disease upon challenge with pathogenic virus, presumably because the vaccination primes the animal's immune system to subsequent virus challenge. Nevertheless, neutralizing antibodies can be detected in the sera of infected mink (44) , and it remains possible that a suitable vaccine might be developed. One means of exploring this possibility would be to express ADV proteins in a eukaryotic system and to study the usefulness of such materials as vaccine candidates.
Development of such a system is possible because the tissue culture-adapted strain of ADV, ADV-G, has been molecularly cloned, and the entire sequence has been determined (5, 6) . In addition, the transcriptional map and program of ADV-G have been studied (2) . As with other parvoviruses, ADV has a linear single-stranded DNA genome, approximately 5,000 bases in length, of negative polarity. Synthesis of a series of nonstructural proteins coded by the left half of the genome is directed by a promoter at map unit 4. The right half of the genome is transcribed under the regulation of a promoter at map unit 36 and encodes two capsid proteins, VP1 and VP2. The amino acid sequence of VP2 is entirely contained within VP1, and transcriptional studies suggest that both proteins are derived from the same spliced mRNA transcript through alternate initiation events (2) . cDNA clones that contain the coding sequences for both VP1 and VP2 have also been prepared, and thus, DNA segments corresponding to the spliced mRNA for VP1 and VP2 are available (2) .
One expression system in which a number of proteins have been expressed is vaccinia virus and other poxviruses (for reviews, see references 23 and 45). Recombinant poxviruses containing foreign viral genes have successfully been used in studies involving the host immune response, and in some cases, vaccination with such viruses has resulted in protection from viral infection (36, 45) .
In this study, we have expressed the ADV structural proteins in recombinant vaccinia viruses, VV:ADSP. Cells infected with VV:ADSP were specifically stained by ADV antiserum when immunohistochemical examination was performed. Characterization of protein from VV:ADSP-infected cells revealed that both the 85-kDa VP1 and the 75-kDa VP2 structural proteins of ADV were expressed and comigrated with proteins expressed by ADV-G when analyzed by immunoblot or radioimmunoprecipitation. These proteins were shown to be transported to the nucleus and assembled into ADV empty capsids. Mice inoculated with VV:ADSP produced ADV-specific antibodies, and some of these animals produced detectable levels of neutralizing antibodies to ADV.
Aleutian disease, in addition to being an interesting model for the pathogenesis of parvovirus infections and persistent viral infections, is also a significant economic problem in the mink industry. Therefore, diagnosis and control of ADV infections are also of importance. ADV infection can be eradicated by culling ADV-seropositive animals from infected herds (17) . Counterimmunoelectrophoresis (CIE) is currently the standard diagnostic test used for the detection of ADV. This test is currently performed by using antigen prepared from ADV-infected cell culture and is highly effective in identifying seropositive animals. VV:ADSP-infected cell lysates were, therefore, used as a source of antigen in a CIE assay and compared favorably with commercially available test antigens.
MATERUILS AND METHODS
Cells and virus. Green monkey kidney cells (CV-1) and Crandell feline kidney (CRFK) cells were grown in Dulbecco's modified Eagle medium with 4.5 mg of glucose per ml and 2 mM L-glutamine, supplemented with 10% fetal bovine serum and 50 ,ug of gentamicin per ml (DMEM-HG). TK-143 cells were grown in DMEM-HG in the presence of 25 ,ug of 5-bromodeoxyuridine per ml. ADV-G was propagated as previously described (10 (Fig. 1) . BglII linkers were added to this fragment following repair of the 3' ends with Klenow fragment. The ADV fragment was ligated into pSC11, and the products were transformed into E. coli JM109. Colonies containing the ADV insert were identified, and the proper orientation of the ADV sequences was verified by restriction enzyme digestions. The clone selected for recombination into vaccinia virus was denoted pXVIII-B-6 (Fig. 1) .
Another construction, denoted pXX-R-14, was developed by replacing the EcoRI-HindIII segment of the ADV-G insert in pXVIII-B-6 with the corresponding segment from a molecular clone of ADV-Utah 1. Plasmids pXVIII-B-6 and pXX-R-14 were propagated and used in the creation of the recombinant vaccinia viruses VV:IL-1 and VV:XXU-1, respectively. These two viruses behaved identically in all assays and, therefore, will collectively be referred to as VV:ADSP throughout this report.
Production and isolation of recombinant vaccinia viruses. Recombinant vaccinia viruses were produced by established procedures (16, 32 (10, 11) . Following preclearing, the aliquots from each sample were incubated with mink anti-ADV or with normal mink serum for 4 h at 4°C while being gently inverted. Fifty microliters of hydrated Sepharose CL4B beads (Pharmacia) (100 mg/ml) was added to each sample, and the incubation was continued for 30 min. The beads were washed five times in lysis buffer, resuspended in 50 RI of Laemmli sample buffer (30) , and boiled for 2 min. The beads were again pelleted by centrifugation, and the proteins within the sample buffer were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% gels. Following electrophoresis, the gels were fixed, dried, and fluorographed by using Entensify (Du Pont). The gels were finally exposed to X-ray film until appropriate exposures were obtained.
Immunohistochemistry. Cells were grown on Lab Tek slides (Nunc), infected at an MOI of 1 PFU per cell, and at 24 h p.i. fixed in cold acetone for 10 min. Immunohistochemistry of the samples was essentially performed as described by Mori et al. (35) .
Buoyant density centrifugation. Construction of plasmid pXVIII-B-6. Plasmid pXVIII-B-6 was constructed by digesting the cDNA containing plasmid pIB21 with XhoI and XbaI and isolating the 2.3-kb fragment containing the ADV structural protein gene. This fragment, corresponding to the R3 mRNA of ADV-G, was then inserted at the unique BglII site directly downstream of the vaccinia virus promoter p7.5 in the vaccinia virus expression vector pSC11 following addition of BglII linkers.
branes as previously described (7, 33) , and reacted with pooled serum from ADV-infected mink.
Samples to be analyzed by electron microscopy were placed as droplets on clean Parafilm. An inverted parlodioncoated 300-mesh copper grid was placed on top of each droplet for 10 min to allow the sample to adsorb. The supernatants were absorbed from the grids with Whatman filter paper. The grids were then washed twice by inverting them on a drop of water and allowing them to wash by diffusion. Samples were stained with 0.5% aqueous uranyl acetate, pH 3.9, for 30 s and examined by using a Hitachi HullEl electron microscope at 75 kV. The images were captured on Kodak S0163 electron film.
CIE. CIE was performed, as previously described (9), with commercial ADV-G antigens (kindly provided by United Vaccines, Madison, Wis., and the Danish Fur Breeders Cooperative) or an ADV-Utah 1 antigen prepared from ADV-Utah 1-infected mink (42) . When VV:ADSP-infected cells were used as the source of antigen, CV-1 cells were seeded in 150-cm2 flasks as described above and infected at an MOI of 0.5 PFU. At 3 days p.i., the cell lysates were prepared by scraping the cells into the media and pelleting.
The supernatants were discarded, and the cell pellets were resuspended in 1 Fig. 2A) , suggesting that high levels of ADV capsid proteins were expressed. The majority of the antigen appeared to be localized in the nucleus, indicating that the antigen was being transported to the nucleus, the site of normal ADV replication (19) . Cells incubated with the normal serum did not react (Fig. 2B) , indicating that the staining was ADV specific. Furthermore, neither uninfected CV-1 cells nor cells infected with VV:WR stained with the anti-ADV serum (data not shown).
In order to define the ADV antigen expressed in W: ADSP-infected CV-1 cells, radioimmunoprecipitation was performed. Radiolabeled cell lysates were incubated with mink anti-ADV or normal mink serum and separated on SDS-polyacrylamide gels. Autoradiography revealed that W:ADSP-infected cells contained two ADV-specific proteins that comigrated with VP1 and VP2 (Fig. 3) . Although W:ADSP-infected cells expressed both structural proteins, VP1 was consistently more abundant than VP2. In contrast, ADV-infected CRFK cells expressed VP1 and VP2 in approximately equal quantities (Fig. 3) . Identical results were also observed when lysates of VV:ADSP-infected cells were analyzed by immunoblot (data not shown).
No ADV-specific proteins were detected in CV-1 cells infected with recombinant vaccinia virus W:IR-1 (a virus which contains an irrelevant insert) or in uninfected CV-1 cells. As expected, the nonstructural protein p71 that is normally produced in an ADV infection (11) was also not detected in the VV:ADSP-infected cells. In addition, when the same samples were reacted with normal mink sera, no bands were observed (Fig. 3) produced implied that both proteins can be expressed from the same ADV mRNA.
Self-assembly of ADV proteins into particles. It has been reported that when the structural proteins of parvoviruses are expressed in either bovine papillomavirus vectors (29, 37) or baculoviruses (12, 25) , these proteins spontaneously assemble into empty particles with physical characteristics of empty virions. To determine whether the ADV proteins expressed by the recombinant vaccinia virus VV:ADSP also assembled into empty particles, VV:ADSP-infected cell lysates were prepared and purified by isopycnic CsCl density gradient centrifugation. Eleven fractions ranging in density from 1.24 to 1.46 g/ml were collected and analyzed by immunoblot and electron microscopy. Immunoblot analysis of the fractions revealed that the bulk of the ADV proteins were located at a density of approximately 1.32 g/ml (Fig. 4, fraction 6 ), which corresponds well to the reported density of 1.33 g/ml for ADV empty particles (10). VP1 was readily observed, and VP2 could be detected in this fraction after longer incubation (data not shown). VP1 was also detected in fraction 5 and after longer incubation could also be observed in fraction 7 (data not shown).
Electron microscopic analysis of the fractions confirmed that large numbers of icosahedral structures, approximately 27 nm in diameter, were also present in fraction 6 (Fig. 5) . Thus, it was highly likely that the ADV structural proteins expressed in W:ADSP-infected cells self-assembled into ADV-like particles with a density similar to that of empty ADV particles. Because VP1 was the predominant ADV protein in this fraction, this result also suggested that the particles contained more VP1 than VP2. Furthermore, we have stored these preparations for several months in CsCl with no noticeable changes in the number of particles present, implying that these particles are quite stable (data not shown). CIE. We wished to determine the usefulness of the ADV antigen expressed by VV:ADSP as a diagnostic antigen. CIE is the standard immunological test for diagnosis of Aleutian disease and was carried out as previously described (9) . We first determined the reactivity of the VV:ADSP antigen to an ADV-positive serum and compared this reactivity with those of other CIE antigens. For these assays, cell lysates from VV:ADSP-or VV:WR-infected cells, as well as two commercial ADV-G antigens, ADV-G DK antigen (a Danish antigen kindly provided by the Danish Fur Breeders Cooperative) and ADV-G USA antigen (kinply provided by United Vaccines), were used. The VV:AD SP antigen was also compared with antigen prepared in our laboratory from ADV-Utah 1-infected mink tissue.
Using a standard ADV-positive serum, fourfold dilutions of these five antigen preparations were tested (Fig. 6) We next tested the VV:ADSP antigen against a panel of mink sera and again compared its reactivity with those of other antigens (Table 1) . In these assays, serial fourfold dilutions of sera from eight experimentally infected mink and two uninfected animals were used. Four of the infected sera were collected at 10 days p.i. (early in infection) and four were collected at 60 days p.i. (in the later stages of the disease). Because the ADV-specific antibody levels are much lower in 10-day p.i. sera than in 60-day p.i. sera (9) , use of these sera would give an indication of the sensitivity of this antigen against both low and high titers in sera. Two of the 10-day sera (mink no. 5 and no. 6) reacted to the VV:ADSP, whereas three of the sera reacted with the ADV-Utah 1 preparation. None of these sera were positive with the standard ADV-G antigen (Table 1) . These results suggested that the VV:ADSP antigen might be superior to the standard ADV-G USA antigen in detecting antibody early in the course of the disease.
All of the antigens reacted with the antibody in mink sera collected at 60 days p.i. However, the VV:ADSP antigen appeared to be more sensitive than the commercially available ADV-G USA antigen in all samples tested, yielding higher titers in all cases (Table 1) . Again, none of the sera reacted with a control lysate from VV:WR-infected cells. The results from this limited comparison suggested that the a Results indicate the highest dilution at which reactivity of the antigen still occurred. VV:WR and VV:ADSP antigens were prepared from 150-cm2 flasks of CV-1 cells. The cells were infected at an MOI of 1 PFU per cell. At 3 days p.i., they were harvested, pelleted, and resuspended in 1 ml of PBS. The samples were freeze-thawed three times and sonicated. Trypsin was added to a final concentration of 162 g/ml, and the lysates were digested for 1 h at 37'C. Following trypsinization, PMSF was added to a final concentration of 1 mM.
The antigen (10 IlI) was loaded into the cathodal well, while 10 Ill of each serum dilution was loaded into the anodal well. The assays were performed as previously described (9) . ADV-Utah 1 antigen used in these assays was prepared as previously described (9) . ADV-G antigen used in these assay was produced by United Vaccines.
b -signifies that these samples were negative at a 1:4 dilution, the lowest dilution assayed.
C All infected animals were inoculated with ADV-Utah 1.
ADV antigen produced in VV:ADSP-infected cells might be superior to the commercially available test antigen. Inoculation of mice with W:ADSP. An ultimate goal of the expression of these proteins in vaccinia virus is to determine the ability of these proteins to protect mink from ADV challenge. As a first step in determining the immunogenicity of W:ADSP-expressed ADV antigens, we investigated the ability of VV:ADSP to induce ADV-specific antibodies in mice. Twelve RML (Swiss-Webster) mice were inoculated intradermally with 108 PFU of either W:ADSP (eight animals) or W:WR (four animals) and were boosted 3 weeks later with a second inoculation. Two weeks following the second inoculation, sera were collected and analyzed for ADV-specific antibodies. When tested against ADV-G-infected CRFK cells by indirect IFA, all eight of the serum samples from W:ADSP-inoculated animals were positive. None of the sera from animals receiving W:WR reacted (Table 2) .
These sera were further analyzed by CIE and tested for neutralizing activity. Three of the eight positive mouse serum samples were positive in the CIE assay. Two of these serum samples had neutralizing activity (Table 2 ). These results indicated that the ADV proteins expressed in W: ADSP-infected cells were immunogenic in mice. In addition, because some of these sera were positive by CIE and were able to neutralize ADV, these results implied that some of the antibodies recognized epitopes present on native ADV particles.
The sera were also analyzed by immunoblot to determine the specific proteins that they recognized. All of the sera were negative at the 1:50 dilution used (data not shown).
DISCUSSION
ADV structural proteins were expressed in recombinant vaccinia viruses. These recombinant viruses directed the PFU of VV:ADSP and boosted 3 weeks later with a similar inoculum. At 2 weeks subsequent to the second inoculation, sera were collected for analysis.
b IFAs were performed with ADV-infected CRFK cells by using a 1:20 dilution of the sera.
c CIE assays were performed by using a standard ADV antigen (United Vaccines) at a 1:4 dilution of the sera.
d ND, these assays were not done. e Highest dilution at which the serum was able to neutralize ADV.
synthesis of both ADV structural proteins, and the proteins self-assembled into particles.
Immunohistochemical examination of cells infected with VV:ADSP revealed that ADV-specific protein was primarily localized in the nuclei of infected cells. Because vaccinia virus replicates in the cytoplasm of infected cells (36) , the presence of the antigen in the nucleus indicated that the proteins were transported to the nucleus, as is normally observed for parvovirus infections (19) . Thus, the appropriate nuclear localization signals must have been present and functional. The amino-terminal end of ADV VP1 contains the amino acid sequence PGKKRSA, which corresponds well with the simian virus 40 T-antigen nuclear localization signal sequence PKKKRKV (18, 27, 31) . Analysis of the VP2-specific sequence revealed the presence of no easily recognizable nuclear transport consensus sequence. Nevertheless, the fact that parvoviruses replicate and assemble in the nucleus suggests that there must also be signal sequences located in the VP2-coding region. Use of this cytoplasmic expression system might be useful in defining the parvovirus sequences required for nuclear transport and localization.
Analysis of W:ADSP-infected cell lysates by either radioimmunoprecipitation or immunoblot revealed that both the 85-kDa VP1 and the 75-kDa VP2 were expressed in infected cells. The fact that vaccinia virus replicates in the cytoplasm and, therefore, is incapable of splicing mRNA transcripts (43) led us to speculate that the single cDNA molecule inserted into the vaccinia virus expression vector can direct synthesis of both VP1 and VP2, as previously proposed (2) . This speculation supports previous work and is in contrast to the reported transcriptional organization of other autonomous parvoviruses in which VP1 and VP2 appear to be synthesized from separate transcripts (13, 24, 34) .
Infection of CV-1 cells with VV:ADSP consistently produced more VP1 than VP2. This finding differs from the results normally obtained from in vitro (11) infection of CRFK cells with ADV-G or in vivo infection of mink kits with ADV-Utah 1 (3), as well as expression of parvovirus proteins in other systems (15, 26, 29, 37) . In all of these cases, VP2 is usually the more abundant species. In the native ADV R3 mRNA transcript, which codes for the capsid proteins, the initiation codon for VP1 is in a poorer translational initiation context (28) than that for VP2, and this initiation constraint was speculated to be the cause for the preferential synthesis of VP2. However, because VV: ADSP-infected cells produce more VP1 than VP2, other factors may also be operative in controlling which AUG is used.
The native ADV R3 mRNA contains 380 residues 5' to the VP1 initiation site. Included in this leader sequence are two minicistrons of 8 and 100 amino acids containing five inframe AUGs. However, the truncated cDNA used to construct VV:ADSP contains no ATGs upstream of the VP1 initiation site. Perhaps, the presence of these small upstream open reading frames influences the recognition of the start sites for the VP1-and VP2-coding sequences as has previously been suggested to occur in a feline parvovirus, feline panleukopenia virus (14) . The possibility also exists that initiation constraints for protein synthesis in vaccinia virusinfected cells differ from those in ADV-infected cells and, therefore, may be involved (4).
The results from immunoblot analysis of fractions collected following partial purification of VV:ADSP-infected cells revealed that the majority of the ADV antigen in these cells was located at a density of 1.32 g/ml and consisted primarily of VP1. These results mirrored those obtained by analysis of whole-cell lysates of VV:ADSP-infected cells, in which VP1 was consistently more abundant than VP2.
Electron microscopic analysis of these fractions confirmed the presence of apparently empty particles with a buoyant density near 1.33 g/ml, the reported density of empty ADV particles (10) . Because the immunoblot of these fractions showed a greater abundance of VP1, the assembled particles produced in VV:ADSP-infected cells likely contained more VP1 than VP2. It is interesting to note that although the ratio between the two structural proteins differed from standard ADV infections, the ability of these proteins to assemble into particles was apparently unaffected. These data coupled with those from other systems suggest that the requirements for parvovirus capsid assembly may not be very stringent (12, 25) . It will be interesting to develop recombinant vaccinia viruses that express only VP1 or VP2 to investigate the requirements for ADV particle assembly.
Examination of the VP1 to VP2 ratios of parvovirus B19 expressed by using a baculovirus eukaryotic expression system revealed that the VP1-to-VP2 ratio in the cell lysates of coinfected cells and the particles produced (12) 
